Aprea Therapeutics Inc.
| NASDAQ: APRE | Healthcare / Biotechnology / USA |
| 4.45 | +0.0300 | +0.68% | Vol 629.43K | 1Y Perf -86.91% |
| Apr 13th, 2021 16:00 DELAYED |
| BID | 4.41 | ASK | 4.47 | ||
| Open | 4.39 | Previous Close | 4.42 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 12.60 | Analyst Rating | Moderate Buy 2.00 | |
| Potential % | 183.15 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 94.28M | Earnings Rating | — | |
| Price Range Ratio 52W % | 0.38 | Earnings Date | 21st May 2021 |
Today's Price Range 4.314.49 | 52W Range 4.3141.12 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -8.06% | ||
| 1 Month | -25.34% | ||
| 3 Months | -14.59% | ||
| 6 Months | -82.72% | ||
| 1 Year | -86.91% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -53.04 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -47.24 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -533.19 | |||
Return on invested Capital Q | -18.42 | |||
Return on invested Capital Y | -52.81 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -2.20 | ||||
| 1.51 | ||||
| - | ||||
| - | ||||
| -3.40 | ||||
| -1.98 | ||||
| 1.51 | ||||
| 3.65 | ||||
| 27.85M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 5.80 | ||||
| 6.00 | ||||
| 0.00 | ||||
| 0.00 | ||||
| -7 393.30 | ||||
| Leverage Ratio | 1.20 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.63 | -0.73 | -15.87 |
| Q03 2020 | -0.77 | -0.58 | 24.68 |
| Q02 2020 | -0.60 | -0.78 | -30.00 |
| Q01 2020 | -0.57 | -0.45 | 21.05 |
| Q04 2019 | -0.39 | -0.64 | -64.10 |
| Q03 2019 | -5.88 | -5.29 | 10.03 |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 21st May 2021 |
| Estimated EPS Next Report | -0.52 |
| Estimates Count | 3 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 629.43K |
| Shares Outstanding | 21.19M |
| Trades Count | 4.68K |
| Dollar Volume | 6.19M |
| Avg. Volume | 1.54M |
| Avg. Weekly Volume | 3.69M |
| Avg. Monthly Volume | 1.38M |
| Avg. Quarterly Volume | 1.48M |
Aprea Therapeutics Inc. (NASDAQ: APRE) stock closed at 4.45 per share at the end of the most recent trading day (a 0.68% change compared to the prior day closing price) with a volume of 640.50K shares and market capitalization of 94.28M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 13 people. Aprea Therapeutics Inc. CEO is Christian S. Schade.
The one-year performance of Aprea Therapeutics Inc. stock is -86.91%, while year-to-date (YTD) performance is -9.55%. APRE stock has a five-year performance of %. Its 52-week range is between 4.31 and 41.12, which gives APRE stock a 52-week price range ratio of 0.38%
Aprea Therapeutics Inc. currently has a PE ratio of -2.20, a price-to-book (PB) ratio of 1.51, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -47.24%, a ROC of -533.19% and a ROE of -53.04%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Aprea Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.52 for the next earnings report. Aprea Therapeutics Inc.’s next earnings report date is 21st May 2021.
The consensus rating of Wall Street analysts for Aprea Therapeutics Inc. is Moderate Buy (2), with a target price of $12.6, which is +183.15% compared to the current price. The earnings rating for Aprea Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aprea Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aprea Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 20.61, ATR14 : 0.54, CCI20 : -146.61, Chaikin Money Flow : -0.01, MACD : -0.68, Money Flow Index : 69.12, ROC : -14.59, RSI : 30.78, STOCH (14,3) : 9.72, STOCH RSI : 0.12, UO : 41.19, Williams %R : -90.28), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aprea Therapeutics Inc. in the last 12-months were:
Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).
CEO: Christian S. Schade
Telephone: +1 617 463-9385
Address: 535 Boylston Street, Boston 02116, MA, US
Number of employees: 13
